What the Liver Told Us: Semaglutide, MASH, and the ESSENCE Trial

A drug most people know from the bathroom scale reversed measurable liver scarring on biopsy. For a disease with almost no treatments, that is a turning point.

Metabolic dysfunction–associated steatohepatitis — MASH — is fatty liver’s dangerous cousin. Fat accumulates, inflammation follows, inflammation lays down scar tissue, and scarring, left unchecked, marches toward cirrhosis, liver failure, and cancer. Roughly one in twenty American adults is thought to have it. For years, doctors could offer little beyond diet, exercise, and patience.

The ESSENCE trial changed that conversation, and it did so with a molecule the public already knew: semaglutide. MASH data now show that the GLP-1 drug can rewrite an organ’s pathology, not just the number on a scale.

What ESSENCE measured — and found

Published in The New England Journal of Medicine in 2025, ESSENCE randomized adults with biopsy-confirmed MASH and moderate-to-advanced fibrosis to weekly semaglutide 2.4 mg or placebo. This is the hard version of a liver trial: outcomes were confirmed by biopsy, the gold standard, not by a blood test or a scan.

At the 72-week interim analysis across the first 800 patients, 62.9% of those on semaglutide saw their steatohepatitis resolve without their fibrosis worsening, against 34.3% on placebo. Fibrosis itself improved in 36.8% of the treated group versus 22.4% on placebo. Roughly a third of treated patients hit both marks at once — inflammation resolved and scarring reduced.

Read that carefully. This is a drug reversing damage a pathologist can see under a microscope, in a disease that had almost nothing.

Two mechanisms, one organ

Why does an appetite drug help the liver? The investigators point to two overlapping actions. Semaglutide eases the metabolic dysfunction that feeds MASH — the obesity, insulin resistance, and lipid overload that drive fat into the liver in the first place. It also appears to calm inflammation more directly, only partly through weight loss. Participants lost around 10% of body weight, which is meaningful but not the whole explanation.

That distinction matters for the field. If the benefit were purely weight, any effective weight-loss method would do. The signal that semaglutide acts on the liver through additional pathways is what makes it a liver drug, not merely a slimming one that happens to help.

The question ESSENCE has not yet answered.

Histology is a surrogate. Resolving steatohepatitis and improving fibrosis on biopsy are strong signs, but the outcomes that ultimately matter are transplants avoided and lives saved. ESSENCE runs to 240 weeks, and that harder question — does the biopsy improvement translate into fewer catastrophes — will not be answered until around 2029.

The interim data were strong enough to move regulators. The FDA granted semaglutide accelerated approval for noncirrhotic MASH with moderate-to-advanced fibrosis in August 2025, making it the first GLP-1 medicine cleared for a liver disease. Accelerated approval is conditional precisely because the long-term outcome data are still pending.

What it means for patients

MASH travels with obesity and type 2 diabetes, conditions semaglutide already treats. A single medicine that can address the weight, the metabolism, and now the liver is a genuine simplification for patients carrying all three — and many do.

The label is specific: noncirrhotic disease, fibrosis stages F2 to F3, not established cirrhosis. As always, the fine print is the medicine. What ESSENCE has already delivered is proof that a peptide can reach into an organ and turn a progressive disease around. The confirmation of what that means for survival is still being written.

Frequently asked questions

Does semaglutide help the liver? In the ESSENCE trial, semaglutide resolved steatohepatitis without worsening fibrosis in about 63% of patients versus 34% on placebo, and improved fibrosis in roughly 37% versus 22% — reversing damage visible on liver biopsy, not just lowering weight.

How does an appetite drug help MASH? Two ways. Semaglutide eases the metabolic dysfunction — obesity, insulin resistance — that drives fat into the liver, and it appears to calm inflammation more directly, only partly through the roughly 10% weight loss participants saw.

Is semaglutide approved for MASH? Yes. The FDA granted Wegovy accelerated approval for noncirrhotic MASH with moderate-to-advanced fibrosis in August 2025, based on the ESSENCE interim results. Confirmation of long-term benefit is expected around 2029.

Sources

1. Sanyal, A.J., Newsome, P.N., et al. “Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis.” New England Journal of Medicine, 2025. ClinicalTrials.gov NCT04822181.
2. U.S. Food and Drug Administration — “FDA Approves Treatment for Serious Liver Disease Known as ‘MASH,’” August 15, 2025.
3. Novo Nordisk A/S — ESSENCE topline and regulatory press releases, 2025.
4. American College of Gastroenterology and AASLD — clinical commentary on ESSENCE, 2025.